SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 68 filers reported holding SYROS PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $339,000 | -23.6% | 75,904 | -6.8% | 0.00% | -25.0% |
| Q2 2021 | $444,000 | -46.8% | 81,474 | -26.9% | 0.00% | -50.0% |
| Q1 2021 | $834,000 | -7.0% | 111,510 | +34.8% | 0.01% | -20.0% |
| Q4 2020 | $897,000 | +73.8% | 82,714 | +41.7% | 0.01% | +25.0% |
| Q3 2020 | $516,000 | -22.3% | 58,358 | -6.4% | 0.01% | -11.1% |
| Q2 2020 | $664,000 | -10.6% | 62,327 | -23.3% | 0.01% | +80.0% |
| Q1 2019 | $743,000 | +71.6% | 81,287 | +4.5% | 0.01% | +66.7% |
| Q4 2018 | $433,000 | -38.9% | 77,768 | +30.6% | 0.00% | -40.0% |
| Q3 2018 | $709,000 | +46.8% | 59,553 | +26.0% | 0.01% | +66.7% |
| Q2 2018 | $483,000 | – | 47,273 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 3,139,895 | $23,486,000 | 4.50% |
| Samsara BioCapital, LLC | 2,189,199 | $14,769,000 | 2.72% |
| Bain Capital Life Sciences Investors, LLC | 5,785,036 | $43,272,000 | 2.45% |
| Omega Fund Management, LLC | 1,562,500 | $11,688,000 | 1.11% |
| Flagship Pioneering Inc. | 2,938,494 | $21,980,000 | 0.35% |
| EcoR1 Capital, LLC | 1,000,000 | $7,480,000 | 0.33% |
| Altium Capital Management LP | 126,702 | $948,000 | 0.26% |
| Nikko Asset Management Americas, Inc. | 5,042,009 | $37,714,000 | 0.18% |
| Artal Group S.A. | 1,025,000 | $7,667,000 | 0.14% |
| Orbimed Advisors | 1,837,500 | $13,745,000 | 0.13% |